var title_f29_28_30144="Caudal retraction panniculus";
var content_f29_28_30144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Caudal retraction of panniculus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panniculus retracted caudad and a supraumbilical incision made.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30144=[""].join("\n");
var outline_f29_28_30144=null;
var title_f29_28_30145="Circumvaginal incision";
var content_f29_28_30145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F78360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F78360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Total vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 429px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cutting around the vagina to the level of the urethra.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30145=[""].join("\n");
var outline_f29_28_30145=null;
var title_f29_28_30146="Congenital histiocytosis";
var content_f29_28_30146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F75074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F75074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital self-healing reticulohistiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Red-brown papules are present on the trunk of this infant with congenital self-healing reticulohistiocytosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30146=[""].join("\n");
var outline_f29_28_30146=null;
var title_f29_28_30147="Multiple uterine leiomyomata";
var content_f29_28_30147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Uterine leiomyomata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross intraoperative photograph of multiple uterine leiomyomata.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mitchel Hoffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30147=[""].join("\n");
var outline_f29_28_30147=null;
var title_f29_28_30148="Follitropin beta (recombinant human follicle stimulating hormone): Patient drug information";
var content_f29_28_30148=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Follitropin beta (recombinant human follicle stimulating hormone): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/52/5958?source=see_link\">",
"     see \"Follitropin beta (recombinant human follicle stimulating hormone): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3882687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Follistim&reg; AQ;",
"     </li>",
"     <li>",
"      Follistim&reg; AQ Cartridge",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3888770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Puregon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you get pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702159",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to follitropin beta or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703455",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Cancer where hormones make it grow, ovarian cysts, adrenal gland disease, thyroid gland disease, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit working out while undergoing ovarian stimulation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of getting pregnant with more than one baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ovarian cyst.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Over stimulation of the ovaries.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699572",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened vials in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may store unopened vials at room temperature. Throw away any unused vials after 3 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699521",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store opened vials in a refrigerator. Throw away after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after 3 months.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10745 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-220.255.2.109-02C9EFC5AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30148=[""].join("\n");
var outline_f29_28_30148=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3882687\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3888770\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029113\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029112\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029116\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029117\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029119\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029115\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029120\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029121\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/52/5958?source=related_link\">",
"      Follitropin beta (recombinant human follicle stimulating hormone): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_28_30149="Prion protein immunoperox prep";
var content_f29_28_30149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F50744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F50744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Medium power photomicrograph of prion protein immunoperoxidase preparation revealing a diffuse and granular synaptic distribution pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     (Immunoperoxidase preparation courtesy of the National Prion Disease Surveillance Center). Courtesy of Henry G Brown, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30149=[""].join("\n");
var outline_f29_28_30149=null;
var title_f29_28_30150="Dexrazoxane: Drug information";
var content_f29_28_30150=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexrazoxane: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/39/8820?source=see_link\">",
"    see \"Dexrazoxane: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/6/10342?source=see_link\">",
"    see \"Dexrazoxane: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Totect&reg;;",
"     </li>",
"     <li>",
"      Zinecard&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F158534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zinecard&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F158556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Cardioprotectant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F158535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of doxorubicin cardiomyopathy:",
"     </b>",
"     I.V.: A 10:1 ratio of dexrazoxane:doxorubicin (dexrazoxane 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     :doxorubicin 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ).",
"     <b>",
"      Note:",
"     </b>",
"     Cardiac monitoring should continue during dexrazoxane therapy; doxorubicin/dexrazoxane should be discontinued in patients who develop a decline in LVEF or clinical CHF.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of anthracycline extravasation:",
"     </b>",
"     I.V.: 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 2 (maximum dose: 2000 mg), followed by 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 3 (maximum dose: 1000 mg); begin treatment as soon as possible, within 6 hours of extravasation",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9645632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/6/10342?source=see_link\">",
"      see \"Dexrazoxane: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Prevention of doxorubicin cardiomyopathy associated with acute lymphoblastic leukemia treatment (high-risk patients; unlabeled use):",
"     </b>",
"     I.V.: A 10:1 ratio of dexrazoxane:doxorubicin (eg, dexrazoxane 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     :doxorubicin 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) was used in patients with high-risk acute lymphoblastic leukemia (Lipshultz, 2010; Moghrabi, 2007; Silverman, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F158536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F730126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Renal function may be estimated using the Cockcroft-Gault formula.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Moderate-to-severe (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Prevention of cardiomyopathy: Reduce dose by 50%, using a 5:1 dexrazoxane:doxorubicin ratio (dexrazoxane 250 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     :doxorubicin 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Anthracycline-induced extravasation: Reduce dose by 50%",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F158537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Prevention of cardiomyopathy: Since doxorubicin dosage is reduced in hyperbilirubinemia, a proportional reduction in dexrazoxane dosage is recommended (maintain a 10:1 ratio of dexrazoxane:doxorubicin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Anthracycline-induced extravasation: Use has not been evaluated in patients with hepatic dysfunction",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 250 mg, 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Totect&reg;: 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zinecard&reg;: 250 mg, 500 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F158517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prevention of doxorubicin cardiomyopathy: Administer doxorubicin within 30 minutes after beginning the infusion with dexrazoxane.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Zinecard&reg;: Administer by rapid drip infusion; do",
"     <b>",
"      not",
"     </b>",
"     administer by I.V. push",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dexrazoxane generic formulation (Bedford Laboratories, Mylan, Inc): Administer by slow I.V push or rapid drip infusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of anthracycline extravasation: Administer I.V. over 1-2 hours; begin infusion as soon as possible, within 6 hours of extravasation. Infusion solution should be at room temperature prior to administration. Infuse in a large vein in an area remote from the extravasation. If extravasation is also being managed with cooling, withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Day 2 and 3 doses should be administered at approximately the same time (&plusmn; 3 hours) as the dose on day 1. For I.V. administration;",
"     <b>",
"      not",
"     </b>",
"     for local infiltration into extravasation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F158561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in NS (Totect&reg;, generic formulations reconstituted with 0.167 M sodium lactate), D",
"     <sub>",
"      5",
"     </sub>",
"     W (generic formulations reconstituted with 0.167 M sodium lactate), LR (Zinecard&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F158515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinecard&reg;: Reduction of the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     and who would benefit from continuing therapy with doxorubicin. (Not recommended for use with initial doxorubicin therapy.)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Totect&reg;: Treatment of anthracycline-induced extravasation.",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F6822564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of the incidence and severity of cardiomyopathy associated with doxorubicin administration (cumulative doses &gt;300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ) in patients with malignancies other than metastatic breast cancer who would benefit from continuing therapy with doxorubicin; reduction of the incidence and severity of cardiomyopathy associated with continued epirubicin administration for advanced breast cancer; prevention of doxorubicin cardiomyopathy associated with acute lymphoblastic leukemia treatment in children",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F158563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zinecard&reg; may be confused with Gemzar&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F158554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Most adverse reactions are thought to be attributed to chemotherapy, except for increased myelosuppression, pain at injection site, and phlebitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Prevention of doxorubicin cardiomyopathy",
"     </b>",
"     (reactions listed are those which were greater in the dexrazoxane arm in a comparison of chemotherapy plus dexrazoxane vs chemotherapy alone):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Fatigue/malaise, fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia, streaking/erythema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Serum amylase increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Granulocytopenia, leukopenia, myelosuppression, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Extravasation, injection site pain, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neurotoxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection, sepsis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Anthracycline extravasation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, fatigue, fever, headache, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Alopecia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypercalcemia, hyponatremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia, leukopenia, neutropenia, neutropenic fever, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hepatic:  Alkaline phosphatase increased, ALT increased, AST increased, bilirubin increased, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site pain/discomfort, phlebitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Renal: Creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pneumonia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Infection",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F158520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinecard&reg;: Use with chemotherapy regimens that do not contain an anthracycline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Totect&reg;: There are no contraindications listed within the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F158504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: May cause mild myelosuppression activity; myelosuppression may be additive with concurrently administered chemotherapeutic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardioprotection: Does not eliminate the potential for anthracycline-induced cardiac toxicity; carefully monitor cardiac function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) have been reported in pediatric patients and some adult patients receiving dexrazoxane in combination with chemotherapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Due to dosage adjustments for doxorubicin in hepatic impairment, a proportional dose reduction in dexrazoxane is recommended to maintain the dosage ratio of 10:1.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal dysfunction (clearance is reduced); dosage adjustment required for Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;40 mL/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dimethylsulfoxide (DMSO): Do not use DMSO in patients receiving dexrazoxane for anthracycline-induced extravasation; may diminish dexrazoxane efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tumor response: Dexrazoxane may interfere with the antitumor effect of chemotherapy when given concurrently with fluorouracil, doxorubicin, and cyclophosphamide (FAC).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: For I.V. administration;",
"     <b>",
"      not",
"     </b>",
"     for local infiltration into extravasation site.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration sequence: When used for the prevention of cardiomyopathy, doxorubicin should be administered within 30 minutes after the beginning of the dexrazoxane infusion.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6219749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimethyl Sulfoxide: May diminish the therapeutic effect of Dexrazoxane.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F158523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies using doses less than the equivalent human dose (based on BSA).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F158543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F158524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the potential for serious adverse reactions in the nursing infant, discontinue nursing during dexrazoxane therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Dexrazoxane Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (1): $255.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $492.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Totect Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $812.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Zinecard Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (1): $281.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (1): $563.72",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F158512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (frequent); liver function; serum creatinine; cardiac function (repeat monitoring at 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     , 500 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     and with every 50 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     of doxorubicin thereafter); monitor site of extravasation",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F158525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ao Nuo Xian (CL);",
"     </li>",
"     <li>",
"      Cardioxane (AR, AT, BR, CN, CO, CZ, DK, EC, ES, FI, FR, GB, GT, HN, IL, IT, KP, MX, NI, PE, PL, PY, SV, UY, VE);",
"     </li>",
"     <li>",
"      Dexarazoxane Martian (AR);",
"     </li>",
"     <li>",
"      Dexrazoxane Chiron (AR);",
"     </li>",
"     <li>",
"      Savene (AT, BE, BG, CH, CZ, DE, DK, EE, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F158503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Derivative of ethylenediaminetetraacetic acid (EDTA); potent intracellular chelating agent. The mechanism of cardioprotectant activity is not fully understood. Appears to be converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated oxygen free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy. In the management of anthracycline-induced extravasation, dexrazoxane may act by reversibly inhibiting topoisomerase II, protecting tissue from anthracycline cytotoxicity, thereby decreasing tissue damage.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F158519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 22 L/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 2-2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (42%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barry EV, Vrooman LM, Dahlberg SE, et al, &ldquo;Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(7):1106-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/18309945/pubmed\" id=\"18309945\" target=\"_blank\">",
"        18309945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brier ME, Gaylor SK, McGovren JP, et al. &ldquo;Pharmacokinetics of Dexrazoxane in Subjects With Impaired Kidney Function,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 2011, 51(5):731-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/20484616/pubmed\" id=\"20484616\" target=\"_blank\">",
"        20484616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hellmann K, &ldquo;Overview and Historical Development of Dexrazoxane,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1998, 25(4 Suppl 10):48-54.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al, &ldquo;American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiotherapy Protectants,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(1): 127-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/19018081/pubmed\" id=\"19018081\" target=\"_blank\">",
"        19018081",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochster HS, &ldquo;Clinical Pharmacology of Dexrazoxane,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1998, 25(4 Suppl 10):37-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/9768822/pubmed\" id=\"9768822\" target=\"_blank\">",
"        9768822",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwok JC and Richardson DR, &ldquo;The Cardioprotective Effect of the Iron Chelator Dexrazoxane (ICRF-187) on Anthracycline-Mediated Cardiotoxicity,&rdquo;",
"      <i>",
"       Redox Rep",
"      </i>",
"      , 2000, 5(6):317-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/11140743/pubmed\" id=\"11140743\" target=\"_blank\">",
"        11140743",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Langer SW, Sehested M, and Jensen PB, &ldquo;Treatment of Anthracycline Extravasation With Dexrazoxane,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2000, 6(9):3680-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/10999761/pubmed\" id=\"10999761\" target=\"_blank\">",
"        10999761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Langer SW, Thougaard AV, Sehested M, et al, &ldquo;Treatment of Anthracycline Extravasation in Mice With Dexrazoxane With or Without DMSO and Hydrocortisone,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2006, 57(1):125-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/16001176/pubmed\" id=\"16001176\" target=\"_blank\">",
"        16001176",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipshultz SE, Scully RE, Lipsitz SR, et al, &ldquo;Assessment of Dexrazoxane as a Cardioprotectant In Doxorubicin-Treated Children With High-Risk Acute Lymphoblastic Leukaemia: Long-Term Follow-Up of a Prospective, Randomised, Multicentre Trial,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(10):950-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/20850381/pubmed\" id=\"20850381\" target=\"_blank\">",
"        20850381",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lopez M and Vici P, &ldquo;European Trials With Dexrazoxane in Amelioration of Doxorubicin and Epirubicin-Induced Cardiotoxicity,&rdquo;",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 1998, 25(4 Suppl 10):55-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/9768825/pubmed\" id=\"9768825\" target=\"_blank\">",
"        9768825",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marty M, Espi&eacute; M, Llombart A, et al, &ldquo;Multicenter Randomized Phase III Study of the Cardioprotective Effect of Dexrazoxane (Cardioxane) in Advanced/Metastatic Breast Cancer Patients Treated With Anthracycline-Based Chemotherapy,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2006, 17(4):614-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/16423847/pubmed\" id=\"16423847\" target=\"_blank\">",
"        16423847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moghrabi A, Levy DE, Asselin B, et al, &ldquo;Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for Children With Acute Lymphoblastic Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(3):896-904.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/17003366/pubmed\" id=\"17003366\" target=\"_blank\">",
"        17003366",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mouridsen HT, Langer SW, Buter J, et al, &ldquo;Treatment of Anthracycline Extravasation With Savene (Dexrazoxane): Results From Two Prospective Clinical Multicentre Studies,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2007, 18(3):546-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/17185744/pubmed\" id=\"17185744\" target=\"_blank\">",
"        17185744",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schuchter LM, Hensley ML, Meropol NJ, et al, &ldquo;2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2002, 20(12):2895-903.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/12065567 /pubmed\" id=\"12065567 \" target=\"_blank\">",
"        12065567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sehested M, et al, &ldquo;Dexrazoxane for Protection Against Cardiotoxic Effects of Anthracyclines,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14:2884.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverman LB, Stevenson KE, O'Brien JE, et al, &ldquo;Long-Term Results of Dana-Farber Cancer Institute ALL Consortium Protocols for Children With Newly Diagnosed Acute Lymphoblastic Leukemia (1985-2000),&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2010, 24(2):320-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/20016537/pubmed\" id=\"20016537\" target=\"_blank\">",
"        20016537",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tebbi CK, London WB, Friedman D, et al, &ldquo;Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2007, 25(5):493-500.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/17290056/pubmed\" id=\"17290056\" target=\"_blank\">",
"        17290056",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tetef ML, Synold TW, Chow W, et al, &ldquo;Phase I Trial of 96-Hour Continuous Infusion of Dexrazoxane I Patients With Advanced Malignancies,&rdquo;",
"      <i>",
"       Clin Cancer Res",
"      </i>",
"      , 2001, 7(6):1569-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/11410492/pubmed\" id=\"11410492\" target=\"_blank\">",
"        11410492",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Venturini M, Michelotti A, Del Mastro L, et al, &ldquo;Multicenter Randomized Controlled Clinical Trial to Evaluate Cardioprotection of Dexrazoxane versus No Cardioprotection in Women Receiving Epirubicin Chemotherapy for Advanced Breast Cancer,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(12):3112-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/8955656/pubmed\" id=\"8955656\" target=\"_blank\">",
"        8955656",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vrooman LM, Neuberg DS, Stevenson KE, et al, &ldquo;The Low Incidence of Secondary Acute Myelogenous Leukaemia in Children and Adolescents Treated With Dexrazoxane for Acute Lymphoblastic Leukaemia: A Report From the Dana-Farber Cancer Institute ALL Consortium,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 2011, 47(9):1373-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/21514146/pubmed\" id=\"21514146\" target=\"_blank\">",
"        21514146",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiseman LR and Spencer CM, &ldquo;Dexrazoxane. A Review of Its Use as a Cardioprotective Agent in Patients Receiving Anthracycline-Based Chemotherapy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1998. 56(3):385-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/28/30150/abstract-text/9777314/pubmed\" id=\"9777314\" target=\"_blank\">",
"        9777314",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9338 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-07BE0D3610-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30150=[""].join("\n");
var outline_f29_28_30150=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158533\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158534\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158556\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158535\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9645632\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158536\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F730126\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158537\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158514\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158500\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158517\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158561\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158515\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6822564\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158563\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158554\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158520\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158504\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299160\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6219749\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158510\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158523\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158543\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158524\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323101\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158512\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158525\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158503\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158519\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9338\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9338|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/39/8820?source=related_link\">",
"      Dexrazoxane: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?10/6/10342?source=related_link\">",
"      Dexrazoxane: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_28_30151="Advanced case 5";
var content_f29_28_30151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1130px;\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Advanced case 5",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 142px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30151=[""].join("\n");
var outline_f29_28_30151=null;
var title_f29_28_30152="Breast exam";
var content_f29_28_30152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61035&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    Breast exam",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 692px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A. The breast exam is started with the patient in a seated position with her arms relaxed. Breast inspection is aided by patient positioning. The patient is asked to raise her arms over her head so the lower part of the breasts can be inspected for asymmetry, skin changes, and nipple inversion or retraction. The patient then puts her hands on her hips and presses in to contract the pectoral muscles so that any other areas of retraction can be visualized.",
"    <br>",
"     B. The regional lymph node exam is completed while the patient is still in the sitting position and includes the cervical, supraclavicular, infraclavicular, and axillary nodal basins.",
"     <br>",
"      C. A bimanual examination of the breasts can be performed while the patient is still in the sitting position. This is especially useful for women with large pendulous breasts.",
"      <br>",
"       D. The breast exam is completed with the patient in a supine position with the ipsilateral arm raised above her head. The area examined should extend from the clavicle superiorly to the rib cage inferiorly and from the sternum medially to the mid-axillary line laterally. A systematic approach ensures that the entire breast is examined. This can be accomplished with either concentric circles, a radial approach, or vertical strips, referred to as the \"lawnmower\" method.",
"       <div class=\"footnotes\">",
"       </div>",
"       <div class=\"reference\">",
"       </div>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30152=[""].join("\n");
var outline_f29_28_30152=null;
var title_f29_28_30153="FL paratrabecular lymphoid infiltration";
var content_f29_28_30153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F85886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F85886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Follicular lymphoma: paratrabecular lymphoid infiltration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 369px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow biopsy shows a paratrabecular lymphoid infiltration pattern, characteristic of follicular lymphoma. Hematoxylin and eosin, 20x magnification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sun T. Flow Cytometry, Immunohistochemistry, and Molecular Genetics for Hematologic Neoplasms, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30153=[""].join("\n");
var outline_f29_28_30153=null;
var title_f29_28_30154="Management and prognosis of infantile spasms";
var content_f29_28_30154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management and prognosis of infantile spasms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/28/30154/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/28/30154/contributors\">",
"     Daniel G Glaze, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/28/30154/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/28/30154/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/28/30154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/28/30154/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/28/30154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infantile spasms (IS) is an age-specific convulsive disorder of infancy and early childhood. Children with IS typically exhibit the electroencephalographic pattern known as hypsarhythmia.",
"   </p>",
"   <p>",
"    The major options for treatment of IS include hormonal therapy, mainly corticotropin (ACTH), and antiepileptic medication, mainly",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    . Pyridoxine is often used as first line therapy for IS in Japan, although there are no randomized controlled trials of this agent as treatment for IS.",
"   </p>",
"   <p>",
"    Treatment of IS has been evaluated in a 2004 and a 2012 American Academy of Neurology (AAN) practice parameter [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], a 2008 Cochrane systemic review [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/3\">",
"     3",
"    </a>",
"    ], and a 2010 United States consensus report [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/4\">",
"     4",
"    </a>",
"    ]. Conclusions were limited by the overall poor methodology of the available studies. Lack of adherence to standardized case definitions and outcome measures is one problem with many studies. Another is that inclusion of a control group is critical, as the natural history of the disease is that clinical spasms subside and electroencephalogram patterns evolve without therapy, yet many clinicians would be reluctant not to treat as there is some observational data that delayed therapy may worsen prognosis. As a result, many questions still remain regarding the mechanism, optimal drug, dose, duration of therapy, and the importance of prompt initiation of treatment after the appearance of spasms.",
"   </p>",
"   <p>",
"    The management and prognosis of IS are reviewed here. The etiology and pathogenesis, clinical features, and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/15/1273?source=see_link\">",
"     \"Etiology and pathogenesis of infantile spasms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=see_link\">",
"     \"Clinical features and diagnosis of infantile spasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143071721\">",
"    <span class=\"h1\">",
"     MONITORING TREATMENT RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The consensus of experts in a 2010 review was that effective treatment of IS is defined by complete cessation of spasms and resolution of hypsarhythmia on electroencephalography (EEG) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/4\">",
"     4",
"    </a>",
"    ]. Both parents and trained observers may miss the occurrence of spasms, especially if they are subtle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features and diagnosis of infantile spasms\", section on 'Spasms'",
"    </a>",
"    .) Less commonly, they may &ldquo;over count&rdquo; imitators of spasms, especially in patients in the symptomatic group. A standard EEG to evaluate interictal activity may miss the hypsarhythmia pattern, which can be variably present in an awake child, but is detected more sensitively in sleep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=see_link&amp;anchor=H4943541#H4943541\">",
"     \"Clinical features and diagnosis of infantile spasms\", section on 'Hypsarhythmia'",
"    </a>",
"    .) As a result, video-EEG monitoring is ideally used to assess treatment response in children with IS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HORMONAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of medical treatment of IS is hormonal therapy with corticotropin (ACTH) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism of action of ACTH and corticosteroids is not known. Administration of ACTH can control spasms in patients with adrenal suppression, suggesting that the effect is independent of adrenal corticosteroid release.",
"   </p>",
"   <p>",
"    Corticotropin may have direct anticonvulsant effects, perhaps via suppression of corticotropin releasing hormone (CRH), an endogenous neuropeptide that may provoke convulsions in immature brain. This theory was suggested by a report in which administration of high-dose ACTH to rats resulted in a reduction of the expression of the CRH gene in amygdala [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. This reduction occurred in animals with and without adrenalectomy and thus was independent of endogenous cortisol production. The effect was reproduced by a peptide fragment of ACTH without corticotrophic activity and abolished by a melanocortin receptor antagonist. In preliminary investigations, ACTH fragments [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/7,8\">",
"     7,8",
"    </a>",
"    ] and CRH receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/9\">",
"     9",
"    </a>",
"    ] have not been effective in patients with intractable IS. However, this result may occur in part because these peptides are not absorbed or do not cross the blood-brain barrier.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Corticotropin (ACTH)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143070909\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticotropin (ACTH,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/33/14871?source=see_link\">",
"     corticotropin injection gel",
"    </a>",
"    ) is recommended as first-line treatment of IS in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In five randomized controlled trials of ACTH therapy for IS, cessation of spasms occurred in 42 to 87 percent of infants, and time from initiation of treatment to cessation of spasms was 7 to 12 days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/10-14\">",
"     10-14",
"    </a>",
"    ]. In most of these studies, the response to ACTH was greater for infants with cryptogenic IS than for infants with symptomatic IS. Relapse rates ranged from 15 to 33 percent. A pharmacogenetic explanation for ACTH unresponsiveness is being sought in ongoing investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143071694\">",
"    <span class=\"h3\">",
"     Formulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACTH formulation most commonly used in the United States and Canada is a natural preparation (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/33/14871?source=see_link\">",
"     corticotropin injection gel",
"    </a>",
"    , HP Acthar, given IM or SC). This preparation is a mixture of peptides and derivatives and is measured in units. A synthetic corticotropin preparation is available in Europe and Asia. A dose of 0.025 mg of synthetic corticotropin is considered to be equivalent to 1 unit of the natural formulation. Data comparing the natural and synthetic forms are not available, but uncontrolled observations suggest that efficacy is similar [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143070723\">",
"    <span class=\"h3\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose of ACTH (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/33/14871?source=see_link\">",
"     corticotropin injection gel",
"    </a>",
"    ) is not known and may differ in individual patients.",
"   </p>",
"   <p>",
"    Two randomized trials reported that response to low-dose therapy (20",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    was comparable to higher doses and resulted in fewer side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/12,14\">",
"     12,14",
"    </a>",
"    ]. In the larger of the trials, 50 patients with recently diagnosed IS were randomly assigned to receive high-dose ACTH (150",
"    <span class=\"nowrap\">",
"     U/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for three weeks, 80",
"    <span class=\"nowrap\">",
"     U/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for two weeks, 80",
"    <span class=\"nowrap\">",
"     U/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every other day for three weeks, 50",
"    <span class=\"nowrap\">",
"     U/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day every other day for one week, and taper to zero over three weeks) or low-dose ACTH (20 to 30",
"    <span class=\"nowrap\">",
"     U/day",
"    </span>",
"    for two to six weeks, then taper to zero over one week) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/12\">",
"     12",
"    </a>",
"    ]. The groups were similar in response to treatment (cessation of spasms and disappearance of hypsarhythmia) (50 versus 58 percent) and rate of relapse. Hypertension occurred more often in the high-dose group (31 versus 4 percent); other side effects were similar between groups. Other retrospective studies also confirm the similar efficacy and fewer adverse side effects using lower dose synthetic ACTH therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A strategy individualizing therapy to treatment response was evaluated in a multicenter study of 30 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/19\">",
"     19",
"    </a>",
"    ]. Treatment was started with low-dose ACTH (3",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day) administered for two to three weeks. In patients who did not respond initially, the dose was increased in intervals to a maximum of 12",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/20\">",
"     20",
"    </a>",
"    ]. Most patients with cryptogenic spasms and one-half of those with symptomatic spasms responded to low-dose ACTH given over the course of two to three weeks. Side effects were related to dose. Other centers have also reported success with a \"step-up\" dosing protocol, with even lower initial doses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach is to initiate ACTH 20 to 30",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    IM (dose",
"    <strong>",
"     not",
"    </strong>",
"    adjusted for body weight). We reevaluate in two weeks and increase to 40",
"    <span class=\"nowrap\">",
"     units/day",
"    </span>",
"    if spasms or hypsarhythmia persist.",
"   </p>",
"   <p>",
"    An alternative approach using a high-dose regimen has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/10,21\">",
"     10,21",
"    </a>",
"    ]. It consists of treatment with ACTH in a dose of 75",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily IM for two weeks. The dose then is tapered as 30, 15, and 10",
"    <span class=\"nowrap\">",
"     units/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    each morning for three days each, then 10",
"    <span class=\"nowrap\">",
"     U/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every other morning for six days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143071115\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of ACTH persists when therapy is discontinued. However, the optimal duration of treatment is uncertain. Although some series suggest that hormonal therapy should be continued for many months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], prolonged therapy may not be necessary. As an example, in a comparison trial of low-dose ACTH and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    in 24 patients, response occurred within two weeks of initiation of therapy in 75 percent of patients who responded [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/11\">",
"     11",
"    </a>",
"    ]. Five patients who responded relapsed within 12 to 33 months with clinical seizures but not hypsarhythmia; four of these responded to a second course of treatment. Many side effects of hormonal therapy are associated with long-term use. (See",
"    <a class=\"local\" href=\"#H143071122\">",
"     'Adverse effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The 2010 consensus statement suggests initiating a taper of ACTH after two weeks of therapy at the maximum dose [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Relapses are not uncommon among patients who responded to an initial treatment course. No data is available to guide therapy in these cases. Typically, a second course (four to six weeks) of the agent that was previously effective in obtaining control is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143071122\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant side effects may occur with ACTH, as they did in 37 and 85 percent of treated patients in two reports [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Side effects include hypertension, immune suppression and infection, electrolyte imbalance, gastrointestinal disturbances, ocular opacities, hypertrophic cardiomyopathy, cerebral atrophy, and growth impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1,11,12,18,26-28\">",
"     1,11,12,18,26-28",
"    </a>",
"    ]. A transient cushingoid appearance, hirsutism, irritability, and sleep disorders also are seen [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/24\">",
"     24",
"    </a>",
"    ]. These changes are reversible upon discontinuation of the drug. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring of patients on ACTH should include measurement of blood pressure (baseline and once weekly) and serum concentrations of glucose, potassium, and sodium (baseline and every other week). The patient should be observed closely and treated promptly for infections:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, infection related to ACTH occurred in 6 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/29\">",
"       29",
"      </a>",
"      ]. Rarely, death due to sepsis directly attributable to ACTH has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/2,24\">",
"       2,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypertension is the most common complication. In one series, hypertension, defined as sustained blood pressure higher than",
"      <span class=\"nowrap\">",
"       140/90",
"      </span>",
"      mmHg, occurred in 25 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/24\">",
"       24",
"      </a>",
"      ]. Intracranial hemorrhage has been associated with hypertension in this condition [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/25\">",
"       25",
"      </a>",
"      ]. High-dose ACTH is associated with increased frequency of hypertension [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/11\">",
"       11",
"      </a>",
"      ]. Reducing the corticosteroid dose does not always result in a sustained reduction of blood pressure.",
"     </li>",
"     <li>",
"      Electrolyte imbalance may depend upon the corticosteroid dose. Hypokalemic alkalosis occurred in as many as 12 percent of patients on high-dose ACTH [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/24\">",
"       24",
"      </a>",
"      ]. In contrast, no significant electrolyte abnormalities were detected by serial laboratory monitoring during low-dose, short-term hormonal therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with IS often have increased irritability during treatment and may have disturbed sleep patterns, although these may be caused in part by the underlying disease. Compared to normal infants, total sleep time and the proportion of REM sleep are reduced in IS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, sleep disturbances may be caused by IS rather than hormonal therapy.",
"   </p>",
"   <p>",
"    Reduced brain size may result from ACTH and corticosteroid therapy. Ventriculomegaly and increased volume of the subarachnoid space, consistent with cerebral atrophy, have been detected on CT scans of patients receiving hormonal treatment for IS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/11,31-34\">",
"     11,31-34",
"    </a>",
"    ]. These changes may persist after termination of therapy. In a trial comparing ACTH and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    , cerebral atrophy was detected by CT scan in 62 percent of patients during treatment; changes persisted in 42 percent six weeks after therapy was stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/11\">",
"     11",
"    </a>",
"    ]. Subdural hematoma, resulting from brain shrinkage, may occur, even during administration of low-dose ACTH therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/35\">",
"     35",
"    </a>",
"    ]. These findings are consistent with studies in animals treated with ACTH and corticosteroids that demonstrate interference with synthesis of brain DNA, RNA, and protein, and reduction in brain size [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The relationship of the changes in brain volume to long-term neurologic outcome of patients with IS is unknown.",
"   </p>",
"   <p>",
"    Patients treated with high-dose and prolonged regimens of glucocorticoid therapy may be at risk for reduced bone density later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/38\">",
"     38",
"    </a>",
"    ], however, there are no studies that indicate whether follow-up is needed to diagnose and treat this condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less costly, easier-to-administer hormonal therapy regimens have been suggested as potential effective alternatives to ACTH. However, most consensus and guideline groups have found the data regarding corticosteroids to be insufficient to recommend their use as first line treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1,4\">",
"     1,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Uncontrolled studies have noted that other hormonal therapies (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/63/17401?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) appear to control spasms in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/24,39-41\">",
"     24,39-41",
"    </a>",
"    ]. Two of these series reported better response rates in cryptogenic as opposed to symptomatic IS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/24,39\">",
"     24,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two randomized controlled trials and other nonrandomized investigations have compared ACTH and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    for the treatment of IS. In general, outcomes have favored ACTH. The following outcomes were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-dose corticotropin was superior in efficacy to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      in a double-masked, crossover trial that randomly assigned 29 infants to receive corticotropin (150",
"      <span class=\"nowrap\">",
"       U/m2",
"      </span>",
"      per day) or prednisone (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) for two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/10\">",
"       10",
"      </a>",
"      ]. Cessation of spasms and elimination of hypsarhythmia on video-EEG were significantly better in the group that received corticotropin compared to the one that received prednisone (87 versus 29 percent).",
"     </li>",
"     <li>",
"      Lower dose corticotropin was equivalent in efficacy to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      in a double-masked, crossover trial that randomly assigned 24 patients with IS to receive corticotropin (20 to 30 units per day) or prednisone (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/11\">",
"       11",
"      </a>",
"      ]. Cessation of spasms and disappearance of hypsarhythmia were similar for the corticotropin and prednisone groups and occurred in 67 percent of the 24 patients.",
"     </li>",
"     <li>",
"      High dose corticotropin was superior in efficacy to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       prednisone",
"      </a>",
"      in the retrospective case study for response measures including cessation of spasms (100 versus 59 percent) and EEG normalization (97 versus 50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An open label trial randomized 107 patients to hormonal treatment (either",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      (40 mg to 60 mg daily) or corticotropin) to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"       vigabatrin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/43\">",
"       43",
"      </a>",
"      ]. The proportion of patients with cessation of spasms on days 13 and 14 of treatment was similar in the 30 prednisolone-treated and the 25 corticotropin-treated patients (70 versus 76 percent). The allocation to either hormonal treatment was not randomized and the study was not powered to detect a difference between hormonal treatment groups.",
"     </li>",
"     <li>",
"      A retrospective comparison of patients treated with either corticotropin or pulsed",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      for three days every four weeks) found comparable efficacy between the two treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adverse effects are generally similar with these agents as with ACTH therapy. (See",
"    <a class=\"local\" href=\"#H143071122\">",
"     'Adverse effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We typically reserve",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    for patients who have not responded to initial therapy with ACTH. We use prednisone (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day PO) for a six-week course. This is based on clinical experience; the 2012 American Academy of Neurology (AAN) practice parameter [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1\">",
"     1",
"    </a>",
"    ], the 2008 Cochrane systemic review [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/3\">",
"     3",
"    </a>",
"    ], and the 2010 United States consensus report [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/4\">",
"     4",
"    </a>",
"    ] did not find sufficient evidence to support a recommendation for use of prednisone or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     ANTIEPILEPTIC DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the exception of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    , antiepileptic drugs (AEDs) are",
"    <strong>",
"     not",
"    </strong>",
"    considered effective as a first-line treatment for IS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vigabatrin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H869818\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     Vigabatrin",
"    </a>",
"    may be effective as initial treatment for IS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/13,43,45-49\">",
"     13,43,45-49",
"    </a>",
"    ]. It is an irreversible inhibitor of GABA-transaminase that raises the concentration of GABA in the central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/50\">",
"     50",
"    </a>",
"    ]. Vigabatrin was approved by the FDA in 2009 for the treatment of infantile spasms. In an earlier AAN practice parameter review, nine prospective studies of vigabatrin were reviewed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/2\">",
"     2",
"    </a>",
"    ]. The time from onset of treatment to cessation of spasms ranged from 12 to 35 days. The time to EEG response ranged from 7 to 35 days, and 11 to 83 percent of children had resolution of hypsarhythmia.",
"   </p>",
"   <p>",
"    The largest experience comes from an uncontrolled retrospective study of 250 infants with IS in which",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    was given as monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/47\">",
"     47",
"    </a>",
"    ]. Initial suppression of spasms was noted in 68 percent. The only placebo-controlled trial of vigabatrin for IS randomly assigned 40 infants to receive vigabatrin or placebo for five days, followed by open treatment with vigabatrin for at least 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/46\">",
"     46",
"    </a>",
"    ]. By the end of the five day double-blind phase, spasm cessation had occurred more frequently in children treated with vigabatrin compared with placebo (35 versus 10 percent) but this result did not achieve statistical significance. At the end of open treatment, spasms had resolved in 42 percent of patients. In prospective randomized controlled trials of vigabatrin, treatment response for children with symptomatic IS ranged from 21 to 44 percent, and response for cryptogenic IS from 27 to 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/13,43,46,48\">",
"     13,43,46,48",
"    </a>",
"    ]. The IS relapse rate ranged from 8 to 20 percent in those trials where relapses were assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/13,46,48\">",
"     13,46,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     Vigabatrin",
"    </a>",
"    has been compared to hormonal therapy in two randomized open-label studies and two retrospective case series; two studies suggested that treatment outcomes were similar, and two suggested that hormonal therapy was superior:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"       Vigabatrin",
"      </a>",
"      was compared to depot ACTH as first-line therapy for IS in 42 infants [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/13\">",
"       13",
"      </a>",
"      ]. Cessation of spasms was more likely with ACTH than with vigabatrin (74 versus 48 percent). However, fewer patients had side effects with vigabatrin than with ACTH (13 versus 37 percent). Relapses occurred in six patients treated with ACTH and in one treated with vigabatrin.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"       Vigabatrin",
"      </a>",
"      (n = 52) was compared to hormonal treatment with either ACTH (tetracosactide depot, n = 25) or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      (n = 30) in a trial of 107 patients that excluded patients with tuberous sclerosis [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/43\">",
"       43",
"      </a>",
"      ]. Cessation of spasms at days 13 and 14 of treatment was more likely with hormonal treatment compared with vigabatrin treatment (73 versus 54 percent). Hormonal treatment was also more effective than vigabatrin for resolution of hypsarhythmia. Adverse events were common with both treatments, but treatment was stopped for only two children receiving hormonal treatment. At 12 to 14 months follow-up, control of spasms was similar in the treatment groups; however cognitive outcomes were better in those who received hormonal treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective case series of 56 consecutive patients treated for IS, 21 were treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"       vigabatrin",
"      </a>",
"      , 21 with ACTH, a similar proportion became spasm-free with elimination of hypsarhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/52\">",
"       52",
"      </a>",
"      ]. Relapse rates were somewhat higher in the ACTH-treated group. Neurodevelopmental outcomes at one-year were similar.",
"     </li>",
"     <li>",
"      In a case series of 72 children with IS, response rates were higher in patients treated with hormonal therapy (17",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/30/35296?source=see_link\">",
"       prednisolone",
"      </a>",
"      , 1 ACTH) compared to those in the 54",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"       vigabatrin",
"      </a>",
"      -treated patients (61 versus 43 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many experts believe that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    is an effective first-line therapy for IS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Concerns regarding toxicity must be balanced against its efficacy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Side effects'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143072126\">",
"    <span class=\"h3\">",
"     Tuberous sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     Vigabatrin",
"    </a>",
"    may be more effective for treating IS in infants with tuberous sclerosis (TS) compared to other etiologies.",
"   </p>",
"   <p>",
"    The 2004 AAN practice parameter for treatment of IS reviewed seven prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/13,47-49,54-56\">",
"     13,47-49,54-56",
"    </a>",
"    ] of infants under three years of age with tuberous sclerosis and infantile spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/2\">",
"     2",
"    </a>",
"    ]. Overall cessation of spasms was seen in 41 of 45 (91 percent) infants treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    , and a 100 percent response rate was seen in five studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/13,48,54-56\">",
"     13,48,54-56",
"    </a>",
"    ]. In a small randomized trial in 22 patients with TS, vigabatrin was superior to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    in controlling infantile spasms, with a 100 percent response rate in the vigabatrin treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Dose and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose and duration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    therapy for IS is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a review of nine prospective studies of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    in IS, doses from 18 to 200",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day were used [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/2\">",
"     2",
"    </a>",
"    ]. The evidence was insufficient to determine if response to vigabatrin was dose dependent. An open label single-masked trial that compared low (18 to 36",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) and high dose (100 to 148",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) regimens, cessation of spasms for seven consecutive days within the first 14 days vigabatrin therapy was significantly greater in the high dose group (36 versus 11 percent) and the time to response was shorter [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/48\">",
"     48",
"    </a>",
"    ]. A randomized study in 221 patients with newly diagnosed IS also suggested greater efficacy for high dose vigabatrin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/57\">",
"     57",
"    </a>",
"    ]. Children were randomly assigned to either high dose (100 to 148",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    or low dose (18 to 36",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    vigabatrin for 14 to 21 days. More patients in the high dose group became seizure free with normalization of a video-EEG (15.9 versus 7.0 percent). The benefit appeared to be maintained in a subsequent open-label treatment phase for up to three years. Adverse events were similar in both groups.",
"   </p>",
"   <p>",
"    Among the studies reviewed in the 2004 AAN practice parameter, the time from initiation of therapy to cessation of spasms ranged from 12 to 35 days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/2\">",
"     2",
"    </a>",
"    ]. In one prospective study of 19 children, withdrawal of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    over a 30 to 60 day period was not associated with relapse within a mean follow-up time of 26 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A typical dosing escalation scale of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    in IS uses an initial dose of 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, escalating to 100 to 150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day as required for clinical response [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/4\">",
"     4",
"    </a>",
"    ]. Efficacy is assessed at two weeks after dose change. The 2010 consensus report suggests that patients who respond to therapy can be continued on the drug for six months, with continued evaluation for toxicity and assessment of risks and benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/4\">",
"     4",
"    </a>",
"    ]. Vigabatrin should be withdrawn earlier in patients who do not respond to treatment.",
"   </p>",
"   <p>",
"    A boxed warning for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    alerts clinicians to safety concerns regarding permanent vision loss with this medication (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Side effects'",
"    </a>",
"    below.). In the United States, vigabatrin is available in a limited number of specialty pharmacies as part of a program called SHARE (Support, Help, And Resources for Epilepsy). Only physicians registered with SHARE can prescribe vigabatrin. Further information about registering with SHARE is available at",
"    <span class=\"nowrap\">",
"     file://www.lundbeckshare.com/pg512_important_steps.aspx.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children treated with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    can develop irreversible retinal dysfunction and visual field constriction [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. The frequency of this complication in children is not known, in part because of the difficulty in assessing visual field loss [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/61\">",
"     61",
"    </a>",
"    ]. Mild to severe bilateral concentric visual field constriction is an important complication of vigabatrin treatment in adults, occurring in approximately 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/62\">",
"     62",
"    </a>",
"    ]. In one series, only 1 of 16 children with IS who were treated with vigabatrin for a mean of 21 months had visual field abnormalities at age 6 to 12 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/63\">",
"     63",
"    </a>",
"    ]. However, the sample size is small, there may have been selection bias, and it is difficult to assess visual fields in young children. The risk of occurrence in adult males is approximately twice that in females. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H16#H16\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Vigabatrin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monitoring for",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    -associated vision loss is challenging as visual fields are difficult to assess in infancy. It is recommended that patients on vigabatrin have a baseline ophthalmologic evaluation at initiation of therapy and every three to six months until three to six months after treatment has been discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     Vigabatrin",
"    </a>",
"    has also been reported to produce MRI abnormalities in infants treated for infantile spasms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. These abnormalities (hyperintense lesions on T2-weighted images with restricted diffusion on diffusion weighted imaging in the basal ganglia, thalamus, brainstem, and dentate nucleus of the cerebellum) appear to be a subclinical, dose-related phenomenon that resolve with discontinuation of vigabatrin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H16#H16\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Vigabatrin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of minor side effects (eg, drowsiness, irritability, hypotonia, sleep disturbance, weight gain) is low and usually does not necessitate discontinuation of the drug. In the three randomized controlled trials of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    , sedation was noted in 9 to 24 percent, irritability in 4 to 9 percent, insomnia in 9 percent, and hypotonia in 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/2\">",
"     2",
"    </a>",
"    ]. Vigabatrin was discontinued in 0 to 6 percent of children in these trials because of side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other AEDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer AEDs may be effective in treatment of IS. However, clinical trials of these agents are needed before they can be recommended for use [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H143070337\">",
"    <span class=\"h3\">",
"     Valproic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reports of treatment with valproic acid have inconsistent results [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/2,66-69\">",
"     2,66-69",
"    </a>",
"    ]. Valproic acid may benefit 40 to 70 percent of patients who do not respond to ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. However, the apparent response may reflect the natural history of IS rather than the effect of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No controlled trials of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    for IS exist [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In one prospective open-label study, cessation of spasms and resolution of hypsarhythmia occurred in 73 and 91 percent of 22 children at six months from onset of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/71\">",
"     71",
"    </a>",
"    ]. A majority responded in two weeks, but 23 percent relapsed, and thrombocytopenia developed in one-third. In the other open label study, cessation of spasms occurred in 72 percent of children at three months from onset of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Zonisamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/52/25415?source=see_link\">",
"     Zonisamide",
"    </a>",
"    is a sulfonamide derivative. Its primary mechanism of action appears to be related to blockage of voltage-dependent sodium and T-type calcium channels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/73\">",
"     73",
"    </a>",
"    ]. In case series, zonisamide was effective in patients with IS, some of whom had failed to respond to pyridoxine or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"     valproate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/74-78\">",
"     74-78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest series,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/52/25415?source=see_link\">",
"       zonisamide",
"      </a>",
"      was given as monotherapy or additional therapy (before corticosteroid treatment but after pyridoxine and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"       clonazepam",
"      </a>",
"      ) for newly diagnosed IS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/75\">",
"       75",
"      </a>",
"      ]. The initial dose, 2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, was increased by 2 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every two to four days until the seizures resolved. The seizures disappeared in 9 of the 27 patients at a mean of five days after onset of therapy, and hypsarhythmia disappeared in most cases. Seizures recurred in four children. No adverse reactions were seen.",
"     </li>",
"     <li>",
"      In a case series restricted to children with symptomatic IS,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/52/25415?source=see_link\">",
"       zonisamide",
"      </a>",
"      was given as add-on, replacement, or primary therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/77\">",
"       77",
"      </a>",
"      ]. Complete control with cessation of spasms and clearing of hypsarhythmia occurred in 6 of 23 children. The mean latency to spasm cessation in responders was 19 days after onset of therapy. All of the 17 children whose spasms did not respond to zonisamide remained refractory to other treatments, including ACTH and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"       vigabatrin",
"      </a>",
"      , at the time of last evaluation. Anorexia occurred in 21 percent of children, but no discontinuations occurred due to adverse events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"     Topiramate",
"    </a>",
"    was tested in an open-label study in patients with refractory IS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/79\">",
"     79",
"    </a>",
"    ]. Patients were given an initial dose of 25 mg per day in addition to their current therapy. The dose was increased by 25 mg every two to three days to a maximum of 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day until spasms were controlled or the maximal tolerated dose was reached. Spasms stopped and hypsarhythmia resolved in 5 of 11 patients. The frequency of spasms was reduced by more than 50 percent in four additional patients. At follow-up, the response was maintained in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/80\">",
"     80",
"    </a>",
"    ]. At a mean of 18 months, eight patients remained on topiramate, including three on topiramate alone. Spasms had stopped in four children and were reduced in seven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/40/39558?source=see_link\">",
"     Tiagabine",
"    </a>",
"    selectively inhibits the reuptake of GABA into neurons and glia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/81\">",
"     81",
"    </a>",
"    ]. Because of its mechanism of action, it may be effective in the treatment of IS. However, it has not been studied for this indication.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/34/3626?source=see_link\">",
"     Lamotrigine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/25/28055?source=see_link\">",
"     felbamate",
"    </a>",
"    also have been used to treat some cases of IS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/82,83\">",
"     82,83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sulthiame is an antiepileptic drug that is available in some countries outside the United States. A randomized, placebo-controlled trial of 37 infants between 3.5 and 15 months of age with newly diagnosed West syndrome (infantile spasms plus hypsarhythmia on EEG) found that infants randomly assigned to receive sulthiame plus pyridoxine had a higher rate of complete response than those assigned to placebo plus pyridoxine (30 versus 0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/84\">",
"     84",
"    </a>",
"    ]. Follow-up in this study was short (only nine days); the long-term efficacy of sulthiame treatment is unknown.",
"   </p>",
"   <p>",
"    Benzodiazepines, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/42/21158?source=see_link\">",
"     nitrazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"     clonazepam",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/34/32296?source=see_link\">",
"     diazepam",
"    </a>",
"    , have been used anecdotally in IS, however, there is no evidence that benzodiazepines are as effective as ACTH or corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/2,85-87\">",
"     2,85-87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     OTHER MEDICAL THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pyridoxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized controlled trials of pyridoxine for the treatment of I [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1\">",
"     1",
"    </a>",
"    ]S. Although infants with West syndrome have been reported to respond to treatment with high-dose pyridoxal phosphate (vitamin B6, 30 to 400 mg daily), vitamin B6 deficiency or dependency has not been documented in this disorder.",
"   </p>",
"   <p>",
"    The response rates to pyridoxine ranged from 13 to 29 percent in two uncontrolled, prospective, open-label studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. One analysis concluded that there is no evidence these response rates are different from the spontaneous remission rate that would be predicted from natural history data [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/2\">",
"     2",
"    </a>",
"    ]. Long-term outcome appears to be favorable in patients who do respond to pyridoxine treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/90\">",
"     90",
"    </a>",
"    ]. Clinical trials with objective measures (eg, video EEG) and comparison to standard ACTH therapy are needed before pyridoxine can be recommended as initial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Ketogenic diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A ketogenic diet may control spasms in cases refractory to first-line treatment. However, only observational data is available to assess its efficacy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study, 23 patients with IS were placed on a ketogenic diet and evaluated at 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/91\">",
"       91",
"      </a>",
"      ]. All except two previously untreated patients were refractory to ACTH, corticosteroids, and AEDs. Seizures, assessed by parental report and EEG, improved &gt;90 percent in 46 percent (three were seizure-free), and &gt;50 percent in all patients. Medications were reduced or discontinued in 57 percent. Development also improved in 57 percent of cases; this correlated with seizure control. EEGs improved in 8 of 16 children who had hypsarhythmia at baseline. Adverse reactions related to the diet occurred in seven children. Limitations of this study include its retrospective design, the lack of video EEG monitoring to assess control of spasms, and, in the absence of controls, interpretation of the results in the context of the natural history of IS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another retrospective study compared the ketogenic diet as first-line therapy for IS in 13 infants to 20 infants treated initially with ACTH [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/92\">",
"       92",
"      </a>",
"      ]. Within one month of treatment 62 percent of diet-treated and 90 percent of ACTH-treated patients were spasm free. Normalization of the EEG occurred at one month in just 9 percent of patients on the diet compared to 53 percent of those taking ACTH. However, side effects (31 versus 80 percent) and relapse rates (12 versus 33 percent) were lower with the diet. EEGs did normalize within five months in all diet-treated patients who were spasm free, while four of the five who did not achieve remission on the diet did so with ACTH or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"       topiramate",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In a prospective case series, 104 infants were started on the ketogenic diet for IS after unsuccessful or partially successful treatment with ACTH, corticosteroids, or AEDs [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/93\">",
"       93",
"      </a>",
"      ]. A greater than 50 percent reduction in spasms was observed in 64 percent at six months and 66 percent at one to two years. A six-month remission of spasms occurred in 37 percent. Improvement in development was reported in 62 percent, and 29 percent were able to reduce medications. Adverse effects of the diet (including reduced linear growth) were noted in 33 percent.",
"     </li>",
"     <li>",
"      A retrospective study found that evolution to Lennox-Gastaut was less common in children who were treated with the ketogenic diet",
"      <span class=\"nowrap\">",
"       (and/or",
"      </span>",
"      hormonal therapy) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/94\">",
"       94",
"      </a>",
"      ]. This observation requires confirmation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Short duration (eight months) administration of the diet was compared to the more traditional duration of at least two years in a randomized trial in 40 patients with IS who became seizure free on the diet [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/95\">",
"     95",
"    </a>",
"    ]. Seizure outcomes at three to five years after study enrollment were similar between the patient groups.",
"   </p>",
"   <p>",
"    While further study is needed before a ketogenic diet can be recommended as initial treatment for IS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1\">",
"     1",
"    </a>",
"    ], it may be considered in cases refractory to other therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=see_link\">",
"     \"The ketogenic diet\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Liposteroid (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/33/35344?source=see_link\">",
"       dexamethasone",
"      </a>",
"      palmitate) appeared beneficial for IS in a few small studies [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/96,97\">",
"       96,97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intravenous immune globulin (IVIG) therapy resulted in complete normalization of IS in 5 of 23 children (21 percent) in a small prospective open label study [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/98\">",
"       98",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One report noted that thyrotropin releasing hormone was beneficial in patients with IS and elevated prolactin levels at baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The combined use of ACTH and magnesium (ACTH 25",
"      <span class=\"nowrap\">",
"       U/d",
"      </span>",
"      + MgSO",
"      <sub>",
"       4",
"      </sub>",
"      0.25",
"      <span class=\"nowrap\">",
"       g/kg/d)",
"      </span>",
"      was reported to be more effective than ACTH alone in a randomized study in 38 infants with IS [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/100\">",
"       100",
"      </a>",
"      ]. At 24 weeks, 63 percent in the ACTH+MgSO",
"      <sub>",
"       4",
"      </sub>",
"      treatment group were reported to be seizure free compared to 53 percent of the ACTH alone. This finding requires independent confirmation.",
"     </li>",
"     <li>",
"      Other treatment combinations (eg, ACTH and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"       vigabatrin",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/28/35264?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/54/27497?source=see_link\">",
"       valproate",
"      </a>",
"      ) appeared effective in small case series but have not been systematically compared to a control group [",
"      <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/101,102\">",
"       101,102",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SURGICAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many patients with IS have diffuse abnormalities, some have a focal cortical structural or metabolic abnormality that may respond to surgical excision [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/103-105\">",
"     103-105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical treatment is considered in such patients when IS is refractory to medical treatment (approximately 30 to 40 percent of patients), when there is neurodevelopmental arrest or regression, and when there is no evidence of diffuse brain damage or degenerative or metabolic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/4\">",
"     4",
"    </a>",
"    ]. Surgery is not considered if the cortical resection would create an unacceptable new neurologic deficit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=see_link&amp;anchor=H33#H33\">",
"     \"Overview of the treatment of seizures and epileptic syndromes in children\", section on 'Epilepsy surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall prognosis for children with IS is poor (",
"    <a class=\"graphic graphic_table graphicRef78369 \" href=\"UTD.htm?14/20/14667\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/24,106,107\">",
"     24,106,107",
"    </a>",
"    ]. The mortality rate is varies from 3 to 33 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/106-108\">",
"     106-108",
"    </a>",
"    ]. Other adverse outcomes include epilepsy, which may be intractable and moderate to severe neurodevelopmental disability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical spasms stop by three years of age in approximately one-half of children with IS and rarely persist after they are five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/109-112\">",
"     109-112",
"    </a>",
"    ]. Hypsarhythmia also tends to resolve with maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/70,109\">",
"     70,109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=see_link&amp;anchor=H2763158#H2763158\">",
"     \"Clinical features and diagnosis of infantile spasms\", section on 'Clinical course'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall, 50 to 90 percent of patients with IS develop other seizure types [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/4,106,107,112,113\">",
"     4,106,107,112,113",
"    </a>",
"    ]. In general, patients with symptomatic IS are more likely to develop other seizure types than those with cryptogenic IS (57.5 versus 35.3) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/114,115\">",
"     114,115",
"    </a>",
"    ] It has also been observed that seizure outcomes are more favorable in cryptogenic versus symptomatic infantile spasms and in those with earlier onset of spasms (&lt;4 months versus 4 to 8 months versus 8 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/16\">",
"     16",
"    </a>",
"    ], although these relationships have not been found in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/116\">",
"     116",
"    </a>",
"    ]. In symptomatic cases, seizure outcome is better in some etiologies than in others. As examples, outcome for seizure control is relatively good in patients with IS and neurofibromatosis type 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/117\">",
"     117",
"    </a>",
"    ] or Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/118,119\">",
"     118,119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Lennox-Gastaut syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 27 to 50 percent of patients with IS develop a severe form of epilepsy known as Lennox-Gastaut syndrome (",
"    <a class=\"graphic graphic_table graphicRef78369 \" href=\"UTD.htm?14/20/14667\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/24,113,120-122\">",
"     24,113,120-122",
"    </a>",
"    ]. This syndrome includes characteristic types of seizures (typical drop attacks and axial tonic seizures) and specific EEG patterns [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/123\">",
"     123",
"    </a>",
"    ]. In one report, Lennox-Gastaut syndrome was preceded by IS in 10 of 25 cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/120\">",
"     120",
"    </a>",
"    ]. In the published literature, only children with symptomatic IS cases have evolved to Lennox-Gastaut syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=see_link&amp;anchor=H8#H8\">",
"     \"Epilepsy syndromes in children\", section on 'Lennox-Gastaut syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Developmental outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Developmental retardation occurs in approximately 85 percent of patients with IS; most have major (50 percent) or minor (40 percent) neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/24,106,109,124-130\">",
"     24,106,109,124-130",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term prognosis for developmental outcome in IS appears to depend upon the underlying disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/24,109,110,114,115,125,129,131,132\">",
"     24,109,110,114,115,125,129,131,132",
"    </a>",
"    ]. In general, outcome is better for patients with cryptogenic than for those with symptomatic IS [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/106,116,133\">",
"     106,116,133",
"    </a>",
"    ]. In one study, 57 infants with IS were followed for 12 to 60 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/115\">",
"     115",
"    </a>",
"    ]. Severe cognitive impairment (developmental score &lt;50) occurred in 44 percent; 28 percent had mild impairment (developmental score &lt;70) or were normal. The mean developmental score was higher in the cryptogenic than the symptomatic group (71.2 versus 48.4). Neurologic deficits, including motor impairment (eg, hypertonia, spasticity, and hemiparesis) and visual",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hearing abnormalities, occurred less often in the cryptogenic group (23.5 versus 75.0 percent). In another case series of 68 children all with symptomatic IS, developmental delay was noted in 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/114\">",
"     114",
"    </a>",
"    ]. Another study in 95 children with IS found that the adjusted odds ratio for the later development of autism spectrum disorder was higher in the symptomatic versus the cryptogenic group (8.73 versus 1.55) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cognitive deficits are also common in children with cryptogenic IS, even when spasms cease soon after onset and do not recur. In one report, neurodevelopment was assessed at four to six years in 15 children whose spasms resolved before one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/134\">",
"     134",
"    </a>",
"    ]. Intelligence was normal in 12 children. However, 5 of the 12 had specific cognitive deficits, including problems with attention, language, memory, and visual motor skills.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Effect of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is possible but unproven that treatment of IS improves developmental and other long-term outcomes; many observational but no randomized studies have reported that treated patients were more likely to have normal intelligence at follow-up than untreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1,23,116,135,136\">",
"     1,23,116,135,136",
"    </a>",
"    ]. The effects of early versus later treatment, dose, and specific agent are also uncertain.",
"   </p>",
"   <p>",
"    Proposed mechanisms underlying improved outcome with hormonal therapy include interruption of a progressive neuroblastic process that leads to mental retardation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/22\">",
"     22",
"    </a>",
"    ] or acceleration of the physiologic rate of maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/23\">",
"     23",
"    </a>",
"    ]. The pretreatment neurologic status may also be important; in one study, normal cognitive outcome was found in all 25 patients who had no or only mild mental deterioration at presentation but in only 3 of 12 patients who had marked or severe deterioration before treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/137\">",
"     137",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data suggest that treatment developmental outcomes may be better with treatment with ACTH rather than",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1\">",
"     1",
"    </a>",
"    ]. In a randomized trial of 107 patients that compared vigabatrin to hormonal treatment, cognitive outcomes at 12 to 14 months were better in those who had no identified underlying cause and had received hormonal treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/51\">",
"     51",
"    </a>",
"    ]. When reassessed at a mean age of four years, developmental and epilepsy outcomes were similar between the two treatment groups; however for those 77 patients with no identified etiology (cryptogenic IS), cognitive outcomes remained better in those assigned to hormonal treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcome may also be better if therapy is started soon after presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1\">",
"     1",
"    </a>",
"    ]. Among cryptogenic cases, normal outcome occurred in more patients treated within one to two months of the onset of seizures compared to those treated after one or two months (70 to 85 versus 20 to 25 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/22,23,129,137,139\">",
"     22,23,129,137,139",
"    </a>",
"    ]. However, in one prospective study that used a defined treatment regimen for ACTH or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    and 24-hour video-EEG monitoring to determine response, the prognosis was poor for long-term outcome independent of response to therapy (cessation of spasms and resolution of hypsarhythmia), treatment agent used (ACTH or prednisone), or delay between presentation and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/106\">",
"     106",
"    </a>",
"    ]. In contrast, in the clinical trial comparing hormonal treatment so",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"     vigabatrin",
"    </a>",
"    , an analysis of the effect of lead time to treatment on outcome found that each increase in category of lead time duration (within 7 days, 8 to 14 days, 15 days to 1 month, 1 to 2 months, greater than 2 months) was associated with worse developmental outcome at four years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/140\">",
"     140",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In some reports, prolonged treatment (10 or more months) with high-dose corticotropin (80 units every two days) appeared to improve the prognosis for mental and motor development [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/22,23,136\">",
"     22,23,136",
"    </a>",
"    ]. However, in a long-term follow-up study of 214 children, prognosis was not improved by larger (120 to 160 units) compared to smaller doses (20 to 40 units) of ACTH, although fewer side effects occurred in the latter.",
"   </p>",
"   <p>",
"    Studies assessing the benefit of therapy on long term outcomes are both conflicting and difficult to evaluate; most of the available studies are retrospective and lack specific treatment courses or objective criteria for response. Because of these limitations, the AAN systematic review of treatment for IS concluded that successful treatment of IS possibly improves the long term prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Outcome in adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little information is available on very-long-term outcome of children with IS. Some adults with a history of IS have normal intelligence and socioeconomic status, as illustrated by one report of 214 children born between 1960 and 1976 who were followed for 20 to 35 years or until death [",
"    <a class=\"abstract\" href=\"UTD.htm?29/28/30154/abstract/141\">",
"     141",
"    </a>",
"    ]. Death occurred in 31 percent at 3 months to 30 years of age. Intelligence was normal or mildly impaired in 24 percent of the survivors, and 33 percent had no seizures. Some patients with normal intelligence and socioeconomic status had symptomatic IS or focal EEG findings. All patients with a good outcome had short delays between presentation and treatment and responded to ACTH therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest treatment with ACTH as the initial treatment in most children with IS (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Of the available therapies, ACTH has the best established efficacy. The optimal dose and duration of treatment is uncertain. (See",
"      <a class=\"local\" href=\"#H143070909\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We typically start with ACTH 20 to 30",
"      <span class=\"nowrap\">",
"       units/day",
"      </span>",
"      IM (dose",
"      <strong>",
"       not",
"      </strong>",
"      adjusted for body weight) and evaluate treatment response in two weeks, increasing the dose to 40",
"      <span class=\"nowrap\">",
"       units/day",
"      </span>",
"      if spasms or hypsarhythmia persist. (See",
"      <a class=\"local\" href=\"#H143070723\">",
"       'Dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of video-EEG to evaluate treatment response is ideal. Clinical observation frequently misses subtle spasms, and shorter EEGs are less sensitive for detecting hypsarhythmia. (See",
"      <a class=\"local\" href=\"#H143071721\">",
"       'Monitoring treatment response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We typically initiate a taper of ACTH after two weeks at the maximum dose used. (See",
"      <a class=\"local\" href=\"#H143071115\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternative approach using uses higher dose ACTH 75",
"      <span class=\"nowrap\">",
"       U/m2",
"      </span>",
"      twice daily IM for two weeks. The dose then is tapered as 30, 15, and 10",
"      <span class=\"nowrap\">",
"       U/m2",
"      </span>",
"      each morning for three days each, then 10",
"      <span class=\"nowrap\">",
"       U/m2",
"      </span>",
"      every other morning for six days. (See",
"      <a class=\"local\" href=\"#H143070723\">",
"       'Dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Side effects of ACTH are common and include hypertension, irritability, infection, reversible cerebral atrophy, and rarely death due to sepsis. Monitoring should include measurement of blood pressure (baseline and once weekly) and serum concentrations of glucose, potassium, and sodium (baseline and every other week). The patient should be observed closely and treated promptly for infections. (See",
"      <a class=\"local\" href=\"#H143071122\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"       Vigabatrin",
"      </a>",
"      is an alternative-first line therapy for IS. It appears to be particularly effective in patients with tuberous sclerosis. However, its efficacy needs to be balanced against the risk of toxicity. (See",
"      <a class=\"local\" href=\"#H869818\">",
"       'Efficacy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H143072126\">",
"       'Tuberous sclerosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Permanent retinal toxicity is a potentially severe side effect of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"       vigabatrin",
"      </a>",
"      , which is available in the United States only under a restricted distribution program (SHARE). Ophthalmologic evaluation and monitoring is required in patients on this agent. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A typical dosing regimen includes an initial dose of 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, escalating to 100 to 150",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day as required for clinical response. Efficacy is assessed at two weeks after dose change. The optimal treatment duration is unknown. Patients who respond to therapy can be continued on the drug for six months. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Dose and administration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alternative therapies that we use for children who do not respond to ACTH include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       Prednisone",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day PO). We typically treat for six weeks with this agent. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Corticosteroids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/27/25015?source=see_link\">",
"       Vigabatrin",
"      </a>",
"      starting at 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Vigabatrin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ketogenic diet may be effective in children who are refractory to ACTH and other therapies. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Ketogenic diet'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is insufficient evidence to recommend any other treatment for IS, including valproic acid,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/42/21158?source=see_link\">",
"       nitrazepam",
"      </a>",
"      , pyridoxine,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/52/25415?source=see_link\">",
"       zonisamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"       topiramate",
"      </a>",
"      , novel therapies (IVIG, liposteroid, TRH), or combination therapies. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Other AEDs'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Pyridoxine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H28\">",
"       'Others'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the infant relapses after termination of therapy, a second course (four to six weeks) of the agent that was effective in obtaining control should be administered. (See",
"      <a class=\"local\" href=\"#H143071115\">",
"       'Duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The overall prognosis for children with IS is poor. Mortality ranges from 3 to 30 percent and most patients will have impaired neurodevelopmental outcome",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      epilepsy (",
"      <a class=\"graphic graphic_table graphicRef78369 \" href=\"UTD.htm?14/20/14667\">",
"       table 1",
"      </a>",
"      ). There is insufficient evidence to conclude that successful treatment of IS improves the long term prognosis, although that is suggested by some observational data. (See",
"      <a class=\"local\" href=\"#H30\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/1\">",
"      Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2012; 78:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/2\">",
"      Mackay MT, Weiss SK, Adams-Webber T, et al. Practice parameter: medical treatment of infantile spasms: report of the American Academy of Neurology and the Child Neurology Society. Neurology 2004; 62:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/3\">",
"      Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst Rev 2008; :CD001770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/4\">",
"      Pellock JM, Hrachovy R, Shinnar S, et al. Infantile spasms: a U.S. consensus report. Epilepsia 2010; 51:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/5\">",
"      Brunson KL, Khan N, Eghbal-Ahmadi M, Baram TZ. Corticotropin (ACTH) acts directly on amygdala neurons to down-regulate corticotropin-releasing hormone gene expression. Ann Neurol 2001; 49:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/6\">",
"      Snead OC 3rd. How does ACTH work against infantile spasms? Bedside to bench. Ann Neurol 2001; 49:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/7\">",
"      Pentella K, Bachman DS, Sandman CA. Trial of an ACTH4-9 Analogue (ORG 2766) in children with intractable seizures. Neuropediatrics 1982; 13:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/8\">",
"      Willig RP, Lagenstein I. [Therapeutic trial with a fragment of ACTH (ACTH 4-10) in early childhood epilepsy (author's transl)]. Monatsschr Kinderheilkd 1980; 128:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/9\">",
"      Baram TZ, Mitchell WG, Brunson K, Haden E. Infantile spasms: hypothesis-driven therapy and pilot human infant experiments using corticotropin-releasing hormone receptor antagonists. Dev Neurosci 1999; 21:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/10\">",
"      Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 1996; 97:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/11\">",
"      Hrachovy RA, Frost JD Jr, Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. J Pediatr 1983; 103:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/12\">",
"      Hrachovy RA, Frost JD Jr, Glaze DG. High-dose, long-duration versus low-dose, short-duration corticotropin therapy for infantile spasms. J Pediatr 1994; 124:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/13\">",
"      Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 1997; 38:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/14\">",
"      Yanagaki S, Oguni H, Hayashi K, et al. A comparative study of high-dose and low-dose ACTH therapy for West syndrome. Brain Dev 1999; 21:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/15\">",
"      Liu ZL, He B, Fang F, et al. Analysis of single nucleotide polymorphisms in the melanocortin-4 receptor promoter in infantile spasms. Neuropediatrics 2007; 38:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/16\">",
"      Hamano S, Yamashita S, Tanaka M, et al. Therapeutic efficacy and adverse effects of adrenocorticotropic hormone therapy in west syndrome: differences in dosage of adrenocorticotropic hormone, onset of age, and cause. J Pediatr 2006; 148:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/17\">",
"      Oguni H, Yanagaki S, Hayashi K, et al. Extremely low-dose ACTH step-up protocol for West syndrome: maximum therapeutic effect with minimal side effects. Brain Dev 2006; 28:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/18\">",
"      Ito M, Aiba H, Hashimoto K, et al. Low-dose ACTH therapy for West syndrome: initial effects and long-term outcome. Neurology 2002; 58:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/19\">",
"      Heiskala H, Riikonen R, Santavuori P, et al. West syndrome: individualized ACTH therapy. Brain Dev 1996; 18:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/20\">",
"      Snead OC 3rd. West syndrome: individualized ACTH therapy, by Heiskala et al. Brain Dev 1996; 18:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/21\">",
"      Baram TZ. What are the reasons for the strikingly different approaches to the use of ACTH in infants with West syndrome? Brain Dev 2001; 23:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/22\">",
"      Lerman P, Kivity S. The efficacy of corticotropin in primary infantile spasms. J Pediatr 1982; 101:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/23\">",
"      Singer WD, Rabe EF, Haller JS. The effect of ACTH therapy upon infantile spasms. J Pediatr 1980; 96:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/24\">",
"      Lombroso CT. A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 1983; 24:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/25\">",
"      Riikonen R, Donner M. ACTH therapy in infantile spasms: side effects. Arch Dis Child 1980; 55:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/26\">",
"      Perheentupa J, Riikonen R, Dunkel L, Simell O. Adrenocortical hyporesponsiveness after treatment with ACTH of infantile spasms. Arch Dis Child 1986; 61:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/27\">",
"      Bobele GB, Ward KE, Bodensteiner JB. Hypertrophic cardiomyopathy during corticotropin therapy for infantile spasms. A clinical and echocardiographic study. Am J Dis Child 1993; 147:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/28\">",
"      Partikian A, Mitchell WG. Major adverse events associated with treatment of infantile spasms. J Child Neurol 2007; 22:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/29\">",
"      Kusse MC, van Nieuwenhuizen O, van Huffelen AC, et al. The effect of non-depot ACTH(1-24) on infantile spasms. Dev Med Child Neurol 1993; 35:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/30\">",
"      Hrachovy RA, Frost JD Jr, Kellaway P. Sleep characteristics in infantile spasms. Neurology 1981; 31:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/31\">",
"      Lagenstein I, Willig RP, K&uuml;hne D. Cranial computed tomography (CCT) findings in children treated with ACTH and dexamethasone: first results. Neuropadiatrie 1979; 10:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/32\">",
"      Maekawa K, Ohta H, Tamai I. Transient brain shrinkage in infantile spasms after ACTH treatment. Report of two cases. Neuropadiatrie 1980; 11:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/33\">",
"      Hara K, Watanabe K, Miyazaki S, et al. Apparent brain atrophy and subdural hematoma following ACTH therapy. Brain Dev 1981; 3:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/34\">",
"      Carollo C, Marin G, Scanarini M, et al. CT and ACTH treatment in infantile spasms. Childs Brain 1982; 9:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/35\">",
"      Ito M, Miyajima T, Fujii T, Okuno T. Subdural hematoma during low-dose ACTH therapy in patients with west syndrome. Neurology 2000; 54:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/36\">",
"      Baier WK. Interference of cortisone and ACTH with brain development? A survey of experimental studies in mice and rats. Neuropadiatrie 1980; 11:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/37\">",
"      Weichsel ME Jr. The therapeutic use of glucocorticoid hormones in the perinatal period: potential neurological hazards. Ann Neurol 1977; 2:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/38\">",
"      Eidlitz-Markus T, Kivity S, Goldberg-Stern H, et al. Effect of high-dose glucocorticosteroid treatment for infantile spasms on quantitative bone parameters later in life. J Child Neurol 2012; 27:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/39\">",
"      Kossoff EH, Hartman AL, Rubenstein JE, Vining EP. High-dose oral prednisolone for infantile spasms: an effective and less expensive alternative to ACTH. Epilepsy Behav 2009; 14:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/40\">",
"      Mytinger JR, Quigg M, Taft WC, et al. Outcomes in treatment of infantile spasms with pulse methylprednisolone. J Child Neurol 2010; 25:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/41\">",
"      Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010; 17:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/42\">",
"      Snead OC 3rd, Benton JW, Myers GJ. ACTH and prednisone in childhood seizure disorders. Neurology 1983; 33:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/43\">",
"      Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004; 364:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/44\">",
"      Haberlandt E, Weger C, Sigl SB, et al. Adrenocorticotropic hormone versus pulsatile dexamethasone in the treatment of infantile epilepsy syndromes. Pediatr Neurol 2010; 42:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/45\">",
"      Chiron C, Dumas C, Jambaqu&eacute; I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997; 26:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/46\">",
"      Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999; 40:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/47\">",
"      Aicardi J, Mumford JP, Dumas C, Wood S. Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Sabril IS Investigator and Peer Review Groups. Epilepsia 1996; 37:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/48\">",
"      Elterman RD, Shields WD, Mansfield KA, et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001; 57:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/49\">",
"      Fejerman N, Cers&oacute;simo R, Caraballo R, et al. Vigabatrin as a first-choice drug in the treatment of West syndrome. J Child Neurol 2000; 15:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/50\">",
"      Petroff OA, Rothman DL, Behar KL, et al. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 1996; 47:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/51\">",
"      Lux AL, Edwards SW, Hancock E, et al. The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. Lancet Neurol 2005; 4:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/52\">",
"      Cossette P, Riviello JJ, Carmant L. ACTH versus vigabatrin therapy in infantile spasms: a retrospective study. Neurology 1999; 52:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/53\">",
"      Mohamed BP, Scott RC, Desai N, et al. Seizure outcome in infantile spasms--a retrospective study. Epilepsia 2011; 52:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/54\">",
"      Vles JS, van der Heyden AM, Ghijs A, Troost J. Vigabatrin in the treatment of infantile spasms. Neuropediatrics 1993; 24:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/55\">",
"      Covanis A, Theodorou V, Lada C, et al. The first-line use of vigabatrin to achieve complete control of infantile spasms. J Epilepsy 1998; 11:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/56\">",
"      Granstr&ouml;m ML, Gaily E, Liukkonen E. Treatment of infantile spasms: results of a population-based study with vigabatrin as the first drug for spasms. Epilepsia 1999; 40:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/57\">",
"      Elterman RD, Shields WD, Bittman RM, et al. Vigabatrin for the treatment of infantile spasms: final report of a randomized trial. J Child Neurol 2010; 25:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/58\">",
"      Capovilla G, Beccaria F, Montagnini A, et al. Short-term nonhormonal and nonsteroid treatment in West syndrome. Epilepsia 2003; 44:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/59\">",
"      Koul R, Chacko A, Ganesh A, et al. Vigabatrin associated retinal dysfunction in children with epilepsy. Arch Dis Child 2001; 85:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/60\">",
"      Iannetti P, Spalice A, Perla FM, et al. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics 2000; 106:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/61\">",
"      Nabbout R. A risk-benefit assessment of treatments for infantile spasms. Drug Saf 2001; 24:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/62\">",
"      K&auml;lvi&auml;inen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001; 15:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/63\">",
"      Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia 2009; 50:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/64\">",
"      Pearl PL, Vezina LG, Saneto RP, et al. Cerebral MRI abnormalities associated with vigabatrin therapy. Epilepsia 2009; 50:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/65\">",
"      Wheless JW, Carmant L, Bebin M, et al. Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy. Epilepsia 2009; 50:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/66\">",
"      Dyken PR, DuRant RH, Minden DB, King DW. Short term effects of valproate on infantile spasms. Pediatr Neurol 1985; 1:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/67\">",
"      Bachman DS. Use of valproic acid in treatment of infantile spasms. Arch Neurol 1982; 39:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/68\">",
"      Pavone L, Incorpora G, La Rosa M, et al. Treatment of infantile spasms with sodium dipropylacetic acid. Dev Med Child Neurol 1981; 23:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/69\">",
"      Barnes SE, Bower BD. Sodium valproate in the treatment of intractable childhood epilepsy. Dev Med Child Neurol 1975; 17:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/70\">",
"      Hrachovy RA, Glaze DG, Frost JD Jr. A retrospective study of spontaneous remission and long-term outcome in patients with infantile spasms. Epilepsia 1991; 32:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/71\">",
"      Siemes H, Spohr HL, Michael T, Nau H. Therapy of infantile spasms with valproate: results of a prospective study. Epilepsia 1988; 29:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/72\">",
"      Fisher E, Siemes H, Pund R, et al. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity. Epilepsia 1992; 33:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/73\">",
"      Schachter SC. The next wave of anticonvulsants. Focus on levetiracetam, oxcarbazepine and zonisamide. CNS Drugs 2000; 14:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/74\">",
"      Suzuki Y, Nagai T, Ono J, et al. Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia 1997; 38:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/75\">",
"      Yanai S, Hanai T, Narazaki O. Treatment of infantile spasms with zonisamide. Brain Dev 1999; 21:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/76\">",
"      Kawawaki H, Tomiwa K, Shiraishi K, Murata R. [Efficacy of zonisamide in West syndrome]. No To Hattatsu 1999; 31:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/77\">",
"      Lotze TE, Wilfong AA. Zonisamide treatment for symptomatic infantile spasms. Neurology 2004; 62:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/78\">",
"      Yum SW, Zhang J, Mo K, et al. A novel recessive Nefl mutation causes a severe, early-onset axonal neuropathy. Ann Neurol 2009; 66:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/79\">",
"      Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998; 39:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/80\">",
"      Glauser TA, Clark PO, McGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 2000; 41 Suppl 1:S91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/81\">",
"      Pellock JM. Managing pediatric epilepsy syndromes with new antiepileptic drugs. Pediatrics 1999; 104:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/82\">",
"      Veggiotti P, Cieuta C, Rex E, Dulac O. Lamotrigine in infantile spasms. Lancet 1994; 344:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/83\">",
"      Hurst DL, Rolan TD. The use of felbamate to treat infantile spasms. J Child Neurol 1995; 10:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/84\">",
"      Debus OM, Kurlemann G, Study group. Sulthiame in the primary therapy of West syndrome: a randomized double-blind placebo-controlled add-on trial on baseline pyridoxine medication. Epilepsia 2004; 45:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/85\">",
"      Dreifuss F, Farwell J, Holmes G, et al. Infantile spasms. Comparative trial of nitrazepam and corticotropin. Arch Neurol 1986; 43:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/86\">",
"      V&ouml;lzke E, Doose H, Stephan E. The treatment of infantile spasms and hypsarrhythmia with mogadon. Epilepsia 1967; 8:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/87\">",
"      Vassella F, Pavlincova E, Schneider HJ, et al. Treatment of infantile spasms and Lennox-Gastaut syndrome with clonazepam (Rivotril). Epilepsia 1973; 14:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/88\">",
"      Ohtsuka Y, Matsuda M, Ogino T, et al. Treatment of the West syndrome with high-dose pyridoxal phosphate. Brain Dev 1987; 9:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/89\">",
"      Pietz J, Benninger C, Sch&auml;fer H, et al. Treatment of infantile spasms with high-dosage vitamin B6. Epilepsia 1993; 34:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/90\">",
"      Ohtsuka Y, Ogino T, Asano T, et al. Long-term follow-up of vitamin B(6)-responsive West syndrome. Pediatr Neurol 2000; 23:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/91\">",
"      Kossoff EH, Pyzik PL, McGrogan JR, et al. Efficacy of the ketogenic diet for infantile spasms. Pediatrics 2002; 109:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/92\">",
"      Kossoff EH, Hedderick EF, Turner Z, Freeman JM. A case-control evaluation of the ketogenic diet versus ACTH for new-onset infantile spasms. Epilepsia 2008; 49:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/93\">",
"      Hong AM, Turner Z, Hamdy RF, Kossoff EH. Infantile spasms treated with the ketogenic diet: prospective single-center experience in 104 consecutive infants. Epilepsia 2010; 51:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/94\">",
"      You SJ, Kim HD, Kang HC. Factors influencing the evolution of West syndrome to Lennox-Gastaut syndrome. Pediatr Neurol 2009; 41:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/95\">",
"      Kang HC, Lee YJ, Lee JS, et al. Comparison of short- versus long-term ketogenic diet for intractable infantile spasms. Epilepsia 2011; 52:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/96\">",
"      Yamamoto H, Asoh M, Murakami H, et al. Liposteroid (dexamethasone palmitate) therapy for West syndrome: a comparative study with ACTH therapy. Pediatr Neurol 1998; 18:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/97\">",
"      Yamamoto H, Fukuda M, Miyamoto Y, et al. A new trial liposteroid (dexamethasone palmitate) therapy for intractable epileptic seizures in infancy. Brain Dev 2007; 29:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/98\">",
"      Echenne B, Dulac O, Parayre-Chanez MJ, et al. Treatment of infantile spasms with intravenous gamma-globulins. Brain Dev 1991; 13:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/99\">",
"      Matsumoto A, Kumagai T, Takeuchi T, et al. Factors influencing effectiveness of thyrotropin-releasing hormone therapy for severe epilepsy in childhood: significance of serum prolactin levels. Epilepsia 1989; 30:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/100\">",
"      Zou LP, Wang X, Dong CH, et al. Three-week combination treatment with ACTH + magnesium sulfate versus ACTH monotherapy for infantile spasms: a 24-week, randomized, open-label, follow-up study in China. Clin Ther 2010; 32:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/101\">",
"      Zafeiriou DI, Kontopoulos EE, Tsikoulas IG. Adrenocorticotropic hormone and vigabatrin treatment of children with infantile spasms underlying cerebral palsy. Brain Dev 1996; 18:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/102\">",
"      Schlumberger E, Dulac O. A simple, effective and well-tolerated treatment regime for West syndrome. Dev Med Child Neurol 1994; 36:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/103\">",
"      Shields WD, Shewmon DA, Chugani HT, Peacock WJ. Treatment of infantile spasms: medical or surgical? Epilepsia 1992; 33 Suppl 4:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/104\">",
"      Kramer U, Sue WC, Mikati MA. Focal features in West syndrome indicating candidacy for surgery. Pediatr Neurol 1997; 16:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/105\">",
"      Moseley BD, Nickels K, Wirrell EC. Surgical outcomes for intractable epilepsy in children with epileptic spasms. J Child Neurol 2012; 27:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/106\">",
"      Glaze DG, Hrachovy RA, Frost JD Jr, et al. Prospective study of outcome of infants with infantile spasms treated during controlled studies of ACTH and prednisone. J Pediatr 1988; 112:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/107\">",
"      Appleton RE. West syndrome: long-term prognosis and social aspects. Brain Dev 2001; 23:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/108\">",
"      Glaze DG, Zion TE. Infantile spasms. Curr Probl Pediatr 1985; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     Lacy JR, Penry JK. Infantile spasms, Raven Press, New York 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/110\">",
"      Jeavons PM, Bower BD, Dimitrakoudi M. Long-term prognosis of 150 cases of \"West syndrome\". Epilepsia 1973; 14:153.",
"     </a>",
"    </li>",
"    <li>",
"     Jeavons PM, Bower BD. The natural history of infantile spasms. Arch Dis Child 1961: 36:17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/112\">",
"      GIBBS EL, FLEMING MM, GIBBS FA. Diagnosis and prognosis of hypsarhythmia and infantile spasms. Pediatrics 1954; 13:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/113\">",
"      Riikonen R. A long-term follow-up study of 214 children with the syndrome of infantile spasms. Neuropediatrics 1982; 13:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/114\">",
"      Montenegro MA, Eck K, Jacob S, et al. Long-term outcome of symptomatic infantile spasms established by video-electroencephalography (EEG) monitoring. J Child Neurol 2008; 23:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/115\">",
"      Koo B, Hwang PA, Logan WJ. Infantile spasms: outcome and prognostic factors of cryptogenic and symptomatic groups. Neurology 1993; 43:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/116\">",
"      Partikian A, Mitchell WG. Neurodevelopmental and epilepsy outcomes in a North American cohort of patients with infantile spasms. J Child Neurol 2010; 25:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/117\">",
"      Motte J, Billard C, Fejerman N, et al. Neurofibromatosis type one and West syndrome: a relatively benign association. Epilepsia 1993; 34:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/118\">",
"      Watanabe K. West syndrome: etiological and prognostic aspects. Brain Dev 1998; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/119\">",
"      Sanmaneechai O, Sogawa Y, Silver W, et al. Treatment outcomes of West syndrome in infants with Down syndrome. Pediatr Neurol 2013; 48:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/120\">",
"      Rantala H, Putkonen T. Occurrence, outcome, and prognostic factors of infantile spasms and Lennox-Gastaut syndrome. Epilepsia 1999; 40:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/121\">",
"      Kurokawa T, Goya N, Fukuyama Y, et al. West syndrome and Lennox-Gastaut syndrome: a survey of natural history. Pediatrics 1980; 65:81.",
"     </a>",
"    </li>",
"    <li>",
"     Weinmann HM. Lennox-Gastaut syndrome and its relationship to infantile spasms (West syndrome). In: The Lennox-Gastaut syndrome, Niedermeyer E, Degen R (Eds), Alan R Liss, New York 1988. p.301.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/123\">",
"      Niedermeyer E. Lennox-Gastaut syndrome. Clinical description and diagnosis. Adv Exp Med Biol 2002; 497:61.",
"     </a>",
"    </li>",
"    <li>",
"     Kellaway P, Frost JD Jr, Hrachovy RA. Infantile spasms. In: Antiepileptic Drug Therapy in Pediatrics, Morselli PL, Pippenger CE, Penry JK (Eds), Raven Press, New York 1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/125\">",
"      Jeavons PM, Harper JR, Bower BD. Long-term prognosis in infantile spasms: a follow-up report on 112 cases. Dev Med Child Neurol 1970; 12:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/126\">",
"      Chevrie JJ, Aicardi J. Convulsive disorders in the first year of life: neurological and mental outcome and mortality. Epilepsia 1978; 19:67.",
"     </a>",
"    </li>",
"    <li>",
"     Kellaway P. Neurologic status of patients with hypsarrhythmia. In: Molecules and Mental Health, Gibbs FA (Ed), JB Lippincott, Philadelphia 1959. p.134.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/128\">",
"      Friedman E, Pampiglione G. Prognostic implications of electroencephalographic findings of hypsarrhythmia in first year of life. Br Med J 1971; 4:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/129\">",
"      Matsumoto A, Watanabe K, Negoro T, et al. Long-term prognosis after infantile spasms: a statistical study of prognostic factors in 200 cases. Dev Med Child Neurol 1981; 23:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/130\">",
"      Pollack MA, Zion TE, Kellaway P. Long-term prognosis of patients with infantile spasms following ACTH therapy. Epilepsia 1979; 20:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/131\">",
"      Golomb MR, Garg BP, Williams LS. Outcomes of children with infantile spasms after perinatal stroke. Pediatr Neurol 2006; 34:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/132\">",
"      Saemundsen E, Ludvigsson P, Rafnsson V. Risk of autism spectrum disorders after infantile spasms: a population-based study nested in a cohort with seizures in the first year of life. Epilepsia 2008; 49:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/133\">",
"      Vendrame M, Guilhoto LM, Loddenkemper T, et al. Outcomes of epileptic spasms in patients aged less than 3 years: single-center United States experience. Pediatr Neurol 2012; 46:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/134\">",
"      Gaily E, Appelqvist K, Kantola-Sorsa E, et al. Cognitive deficits after cryptogenic infantile spasms with benign seizure evolution. Dev Med Child Neurol 1999; 41:660.",
"     </a>",
"    </li>",
"    <li>",
"     Sorel L. Treatment of hypsarrhythmia with ACTH. In: Molecules and Mental Health, Gibbs FA (Ed), JB Lippincott, Philadelphia 1959.",
"    </li>",
"    <li>",
"     Hagberg B. The nosology of epilepsy in infancy and childhood. In Birkmayer W (ed): \"Epileptic Seizures--Behavior--Pain.\" Bern, Switzerland: Huber 1976.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/137\">",
"      Kivity S, Lerman P, Ariel R, et al. Long-term cognitive outcomes of a cohort of children with cryptogenic infantile spasms treated with high-dose adrenocorticotropic hormone. Epilepsia 2004; 45:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/138\">",
"      Darke K, Edwards SW, Hancock E, et al. Developmental and epilepsy outcomes at age 4 years in the UKISS trial comparing hormonal treatments to vigabatrin for infantile spasms: a multi-centre randomised trial. Arch Dis Child 2010; 95:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/139\">",
"      Hamano S, Yoshinari S, Higurashi N, et al. Developmental outcomes of cryptogenic West syndrome. J Pediatr 2007; 150:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/140\">",
"      O'Callaghan FJ, Lux AL, Darke K, et al. The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study. Epilepsia 2011; 52:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/28/30154/abstract/141\">",
"      Riikonen R. Long-term otucome of West syndrome: a study of adults with a history of infantile spasms. Epilepsia 1996; 37:367.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6186 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30154=[""].join("\n");
var outline_f29_28_30154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H143071721\">",
"      MONITORING TREATMENT RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HORMONAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Corticotropin (ACTH)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H143070909\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H143071694\">",
"      - Formulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H143070723\">",
"      - Dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H143071115\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H143071122\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      ANTIEPILEPTIC DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vigabatrin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H869818\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H143072126\">",
"      - Tuberous sclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Dose and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other AEDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H143070337\">",
"      - Valproic acid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Zonisamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Topiramate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      OTHER MEDICAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pyridoxine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Ketogenic diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SURGICAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Lennox-Gastaut syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Developmental outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Effect of treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Outcome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6186\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6186|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/20/14667\" title=\"table 1\">",
"      Long term outcomes in infantile spasms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/2/1063?source=related_link\">",
"      Clinical features and diagnosis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/62/33769?source=related_link\">",
"      Epilepsy syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/15/1273?source=related_link\">",
"      Etiology and pathogenesis of infantile spasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/32/37386?source=related_link\">",
"      Overview of the treatment of seizures and epileptic syndromes in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/30/15850?source=related_link\">",
"      The ketogenic diet",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_28_30155="Lamivudine HBV children";
var content_f29_28_30155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Efficacy of lamivudine for chronic hepatitis B virus infection in children*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Response at 52 weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        Placebo (n = 95) number, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lamivudine (n = 191) number, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Virologic response",
"       </td>",
"       <td>",
"        12 (13)",
"       </td>",
"       <td>",
"        44 (23)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sustained normalization of serum ALT",
"       </td>",
"       <td>",
"        11 (12)",
"       </td>",
"       <td>",
"        100 (55)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Virologic response and acquisition of anti-HBe",
"       </td>",
"       <td>",
"        12 (13)",
"       </td>",
"       <td>",
"        42 (22)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of HBeAg",
"       </td>",
"       <td>",
"        14 (15)",
"       </td>",
"       <td>",
"        50 (26)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HBV DNA undetectable",
"       </td>",
"       <td>",
"        15 (16)",
"       </td>",
"       <td>",
"        117 (61)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loss of HBsAg",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        3 (2)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ALT: alanine aminotransferase; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus; HBsAg: hepatitis B s antigen.",
"     <br>",
"      * All differences were statistically significant.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Jonas MM, Kelley DA, Mizerski J, et al. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346:1706.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30155=[""].join("\n");
var outline_f29_28_30155=null;
var title_f29_28_30156="Zoonoses from Cats B";
var content_f29_28_30156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Zoonoses cats, continued",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Transmission",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Human symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Feline symptoms",
"       </td>",
"       <td class=\"subtitle1\">",
"        Geographic distribution",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Aerosol",
"       </td>",
"       <td>",
"        Bordetella bronchiseptica",
"       </td>",
"       <td>",
"        Asymptomatic to upper respiratory tract infections to pneumonia",
"       </td>",
"       <td>",
"        Kennel cough",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coxiella burnetii",
"       </td>",
"       <td>",
"        Q fever, including a self-limited flu-like illness, +/- pneumonia, +/- hepatitis, +/- endocarditis",
"       </td>",
"       <td>",
"        Asymptomatic; infection may cause abortion or rapid death of newborn kittens",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Tick or flea bites",
"       </td>",
"       <td>",
"        B. burgdorferi",
"       </td>",
"       <td>",
"        Lyme disease",
"       </td>",
"       <td>",
"        Lyme disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ehrlichia chaffeensis and Anaplasma phagocytophilum",
"       </td>",
"       <td>",
"        Ehrlichiosis Anaplasmosis",
"       </td>",
"       <td>",
"        Asymptomatic or similar to human disease",
"       </td>",
"       <td>",
"        North America Few cases Europe, Africa, Mexico",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Babesia microti (United States); Babesia divergens (Europe)",
"       </td>",
"       <td>",
"        Babesiosis",
"       </td>",
"       <td>",
"        Asymptomatic or similar to human disease",
"       </td>",
"       <td>",
"        Focal areas of United States and Europe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yersinia pestis",
"       </td>",
"       <td>",
"        Plague",
"       </td>",
"       <td>",
"        Fever, loss of appetite, can have severe illness",
"       </td>",
"       <td>",
"        Majority in south central United States",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Francisella tularensis",
"       </td>",
"       <td>",
"        Tularemia",
"       </td>",
"       <td>",
"        Fever, loss of appetite, can have severe illness",
"       </td>",
"       <td>",
"        Worldwide In the United States (Arkansas, Missouri Oklahoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Direct contact",
"       </td>",
"       <td>",
"        Sporothrix schenckii",
"       </td>",
"       <td>",
"        Sporotrichosis",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Microsporum canis",
"       </td>",
"       <td>",
"        Dermatophyte; ringworm",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine",
"       </td>",
"       <td>",
"        Leptospira interrogans",
"       </td>",
"       <td>",
"        Leptosiprosis, subclinical to severe, potentially fatal illness",
"       </td>",
"       <td>",
"        Similar to human disease",
"       </td>",
"       <td>",
"        Worldwide",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30156=[""].join("\n");
var outline_f29_28_30156=null;
var title_f29_28_30157="Tests for diagnosing HIV I";
var content_f29_28_30157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74816%7EID%2F54839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74816%7EID%2F54839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spectrum of available tests for the diagnosis of HIV-1 (I)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Assay",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD4 counts",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent positive, sensitivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Routine serology",
"       </td>",
"       <td>",
"        &gt;3 mos post viral transmission",
"       </td>",
"       <td>",
"        &gt;99.3-99.7",
"       </td>",
"       <td>",
"        Readily available and inexpensive. Specificity is 99.7 (MMWR 1990; 39:380) or higher (NEJM 1988; 319:961).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapid test SUDS (Murex Diagnostics, Norcross, GA)",
"       </td>",
"       <td>",
"        &gt;3 mos post viral transmission",
"       </td>",
"       <td>",
"        &gt;99",
"       </td>",
"       <td>",
"        Advantage is test results are available in &le;10 min. Specificity is 99.6, so positive tests should be confirmed. Highly sensitive so negative tests do not usually require confirmation. Other rapid tests are available but are not FDA approved (Int J STD AIDS 1997; 8:192; Vox Sang 1997; 72:11).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        p24 antigen",
"       </td>",
"       <td>",
"        200-500/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        10-20",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Measures free viral antigen by EIA and indicates high viral load. Acid treatment increases detection of p24 antigen due to its release from immune complexes. These tests are infrequently used in clinical practice due to relative insensitivity and because their use is largely supplanted by quantitative plasma HIV RNA assays",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;200/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        37-95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Immune complex-disassociated p24 (ICD p24)",
"       </td>",
"       <td>",
"        200-500/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        30-70",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;200/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        75-85",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral blood mononuclear cell culture (PMBC culture)",
"       </td>",
"       <td>",
"        &lt;500/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        95-100",
"       </td>",
"       <td>",
"        Technique is viral isolation by co-cultivation of patients PBMC with PHA-stimulated donor PBMC with IL-2 over 28 days. Expensive and labor-intensive. May be qualitative or quantitative. Main use of qualitative technique is viral isolation for further analysis and for HIV detection in infants. Quantitative results correlate with stage: Mean titer is 2000/10",
"        <sup>",
"         4",
"        </sup>",
"        cells in asymptomatic patients and 2260/10",
"        <sup>",
"         4",
"        </sup>",
"        cells in patients with AIDS (NEJM 1989; 321:1621; Lancet 1998). The greatest potential use is for therapeutic monitoring in patients in clinical trials who have no detectable virus by quantitative HIV RNA.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Barlett, JG. Medical Management of HIV Infection. Port City Press, Baltimore, MD 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Spectrum of available tests for the diagnosis of HIV-1 (II)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Assay",
"       </td>",
"       <td class=\"subtitle1\">",
"        CD4 counts",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent positive, sensitivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DNA PCR assay",
"       </td>",
"       <td>",
"        All stages",
"       </td>",
"       <td>",
"        &gt;99",
"       </td>",
"       <td>",
"        Qualitative DNA PCR is used to detect cell-associated",
"proviral DNA; primers are commercially available from Roche",
"Laboratories. Sensitivity (&gt;99 percent) and specificity (98 percent) are reduced",
"compared to routine serology. This is not considered sufficiently",
"accurate for diagnosis without confimation (Ann Intern Med 1996;",
"124:803). Main use is viral detection in: neonatal HIV and challenged",
"or indeterminant serologic tests.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Quantitative HIV RNA",
"       </td>",
"       <td>",
"        &gt;200/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Quantitation",
"of plasma RNA using reverse transcription and then amplification by",
"PCR. Results are in copies/mL. A 3-fold change is considered",
"significant. This is the preferred test for staging and therapeutic",
"monitoring. There are three techniques and suppliers of reagents: HIV RNA PCR (Roche), bDNA (Chiron), and NASBA (Organon).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;200/mm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        98-100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Salivary test (OraSure Test System)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &gt;99",
"       </td>",
"       <td>",
"        Salivary collection device to collect IgG for EIA and Western blot. Advantage is avoidance of phlebotomy. Sensitivity and specificity comparable to standard serology (JAMA 1997; 227:254).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine test (Calypte 1)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &gt;99",
"       </td>",
"       <td>",
"        Used for EIA test only, so positive results must be verified by serology. Must be administered by a physician. Cost is low - about $4/test.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Barlett, JG. Medical Management of HIV Infection. Port City Press, Baltimore, MD 1998.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30157=[""].join("\n");
var outline_f29_28_30157=null;
var title_f29_28_30158="Algorithm for NMBAs in ICU";
var content_f29_28_30158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59945&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Use of neuromuscular blocking agents (NMBAs) in the ICU",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 456px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Monitor paralysis using a peripheral nerve stimulator, protect eyes and pressure points, and address deep venous thrombosis prophylaxis. NMBAs should be administered using an initial bolus followed by continuous infusion. Reassess indication for continued NMBA every 12 to 24 hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Murray, MJ, Cowen, J, Erstad, B, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 2002; 20:142. Official Journal of the Society of Critical Care Medicine, Copyright &copy; 2002 Society of Critical Care Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30158=[""].join("\n");
var outline_f29_28_30158=null;
var title_f29_28_30159="Color flow doppler of aortic dissection";
var content_f29_28_30159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/50117/teecdoad_conv.mp4?title=Color+flow+doppler+of+aortic+dissection\" style=\"width:431px;height:322px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Color flow doppler of aortic dissection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 251px; height: 280px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram with color flow Doppler shows the intimal flap separating the true and false lumens. A jet of blood can be seen going from the true to the false lumen and spontaneous echo contrast in the false lumen is appreciated, suggesting turbulent blood flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_28_30159=[""].join("\n");
var outline_f29_28_30159=null;
